The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs–TKIs: A Retrospective Multicentric Study
Open Access
- 27 September 2024
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (10) , 1030
Abstract
Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine–kinase inhibitor (TKI). Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI–TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6–12–18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety. Results: After a median follow-up of 24 months, 6–12–18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded. Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs–TKIs combination and SBRT upon oligoprogressive sites in mRCC.Keywords
This publication has 26 references indexed in Scilit:
- Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of UrologyThe Lancet Oncology, 2024
- Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney CancerEuropean Urology Oncology, 2022
- Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter StudyEuropean Urology, 2021
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThe Lancet Oncology, 2020
- Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature, 2015
- Radiation Therapy to Convert the Tumor Into an In Situ VaccineInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Outcomes and Clinicopathologic Variables Associated With Late Recurrence After Nephrectomy for Localized Renal Cell CarcinomaUrology, 2011
- Survival after complete surgical resection of multiple metastases from renal cell carcinomaCancer, 2011